07 / 09 / 2020
Because of metastatic development of the disease, among other characteristics, and regardless of survival data, breast cancer was shown to be particularly difficult to treat. However, metastases as well as resistance to therapies continue to be a great challenge and the development of new therapeutic strategies is increasingly necessary.
04 / 16 / 2020
Explicyte’s expertise and advanced technologies have been harnessed so as to build a cell-based service platform for immuno-oncology (IO) assessment and drug discovery.
03 / 05 / 2020
New explicyte publication in frontiers in Immunology!
02 / 20 / 2020
B cells to the forefront of cancer immunotherapy
01 / 07 / 2020
Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
09 / 12 / 2019
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by the mobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
06 / 27 / 2019
Relying on our validated in vitro immune cell activation assay based on the HTRF quantitation of key cytokine release, we recently documented functional characterization of PD1 blockade.